Cardiometabolic Health Congress
Cardiometabolic Health Congress
October 13, 2019
3 min watch
Save

VIDEO: Potassium-binding agents help enable tolerance of HF medications

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

CHICAGO — In this video exclusive, Cardiology Today Editorial Board Member Ileana L. Piña, MD, MPH, discussed her Cardiometabolic Health Congress workshop on the role of potassium-binding agents in optimizing guideline-directed therapy for HF.

Piña, professor of medicine at Wayne State University, clinical professor of medicine at Central Michigan University and director of CVD research and academic affairs and regional and national director of HF at Detroit Medical Center, said the workshop focused on complications that prevent some clinicians from starting patients on guideline-directed renin-angiotensin-aldosterone system inhibitors for treatment of HF, and how potassium-binding agents can alleviate these.

Watch the video for more.